Related Experiment Videos
Long-Term Mobile-Based Glycemic Intervention for Secondary Prevention in Patients With Diabetes Undergoing Surgical
Yangwu Song1, Yifeng Nan1, Xieraili Tiemuerniyazi1
1Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital, Beilishi Road No. 167, Xicheng District, Beijing, 100037, China, +86 101088322261.
Journal of Medical Internet Research
|June 30, 2026
Summary
Mobile health tools modestly improved glycemic control in post-coronary artery bypass grafting patients with diabetes. Smartphone app interventions showed a significant reduction in HbA1c, though clinical relevance requires further study.
Area of Science:
- Cardiology
- Digital Health
- Diabetes Management
Background:
- Suboptimal glucose control is prevalent in post-coronary artery bypass grafting (CABG) patients in low- and middle-income countries.
- Poor adherence to healthy lifestyles and medications contributes to poor glycemic outcomes.
- Evidence on mobile health interventions for secondary prevention in this high-risk population is limited.
Purpose of the Study:
- To evaluate the effectiveness of mobile health tools for long-term glycemic management in post-CABG patients with diabetes mellitus.
- To assess the impact of a smartphone app intervention on glycosylated hemoglobin (HbA1c) levels.
- To investigate the role of digital health in secondary prevention for cardiovascular patients.
Main Methods:
- A multicenter, randomized controlled trial (GUIDEME) involving 1066 patients with diabetes post-CABG.
- Intervention group received conventional education plus smartphone app-delivered health education and medication reminders for 6 months.
- Control group received conventional health education only.
Main Results:
- A modest but statistically significant reduction in HbA1c was observed in the intervention group compared to the control group (adjusted difference -0.13%, P=.04).
- High medication adherence was noted in the intervention group (96.1%) versus the control group (93.2%).
- Despite low active user rates (14.9%), the intervention showed a positive impact on glycemic control.
Conclusions:
- Smartphone app-based health education and medication reminders led to a statistically significant, albeit modest, improvement in HbA1c.
- The clinical significance of this modest HbA1c reduction warrants further investigation.
- Mobile health interventions show potential for improving glycemic control in post-CABG patients with diabetes.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...